Kyle Guse's Insider Trades & SAST Disclosures

Kyle Guse's most recent trade in Plus Therapeutics Inc was a trade of 922 Common Stock done . Disclosure was reported to the exchange on July 1, 2026.

Share

Note

This is a custom search result for pattern Kyle Guse.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.

All Superstars

"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches "Balanced Fund" but not "Balanced Growth Fund" Balanced Fund: Use this format without quotation marks to search for all funds related to the term "Balanced Fund" The results may include "Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".

Stock	Client Name	Client Category	Action	Reported to Exchange	Quantity	Post Transaction Holding	Traded %	Avg. Price	Value	Security Type
Plus Therapeutics Inc	Kyle Guse	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	01 Jul 2026	922	922 (0%)	0%		0	Common Stock
Plus Therapeutics Inc	Kyle Guse	Director	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	01 Jul 2026	922	2,764	-		-	Restricted Stock Units
Plus Therapeutics Inc	Kyle Guse	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	14 May 2026	3,686	3,686	-		-	Stock Option (Right to Buy)
Plus Therapeutics Inc	Kyle Guse	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	14 May 2026	3,686	3,686	-		-	Restricted Stock Units
Plus Therapeutics Inc	Kyle Guse	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	13 Aug 2025	297,794	297,794	-		-	Stock Option (Right to Buy)
Plus Therapeutics Inc	Kyle Guse	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	13 Aug 2025	40,000	40,000	-		-	Stock Option (Right to Buy)
Atossa Therapeutics Inc	Kyle Guse	CFO, Gen Counsel and Secretary	Grant, award, or other acquisition of securities at price $ 0.00 per share.	02 Mar 2023	557,900	557,900	-		-	Stock Option (right to buy)
Atossa Therapeutics Inc	Kyle Guse	CFO, Gen Counsel and Secretary	Grant, award, or other acquisition of securities at price $ 0.00 per share.	24 Feb 2022	746,667	746,667	-		-	Stock Option (right to buy)

*All Values are in $ Million

Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures

Data as reported to USA Exchanges

View All The Insider Trades